#FDA approval

Moderna Surges 125% Year-to-Date: What's Fueling the Remarkable Comeback?

Moderna shares have surged 125% year-to-date, driven by a unanimous FDA advisory committee vote on its mRNA flu vaccine and major strategic restructuring moves. Wall Street remains cautious despite the rally.

June 29, 2026